<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813705</url>
  </required_header>
  <id_info>
    <org_study_id>PRR-202103</org_study_id>
    <nct_id>NCT04813705</nct_id>
  </id_info>
  <brief_title>18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Multicenter Phase II Study of 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taizhou Enze Medical Center (Group) Enze Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taizhou Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose&#xD;
      radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled patients with complete metabolic response (CMR) and more than 70% partial metabolic&#xD;
      response (PMR) according to PERCIST criteria at the 25th fraction will receive intensity&#xD;
      modulated radiation therapy (IMRT) of reduced-dose (prescribed dose, 63.6 Gy, 2.12 Gy per&#xD;
      fractions, 30 fractions), for those who with ≤70% PMR will receive conventional dose&#xD;
      (prescribed dose, 70Gy, 2.12 Gy per fractions, 33 fractions).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local-regional recurrence free survival (LRFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The LRFS is evaluated and calculated from the date of initiation of treatment until the day of first locoregional relapse or until the date of the last follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>The OS was defined as the duration from the date of of initiation of treatment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Progress-free survival is calculated from the date of initiation of treatment to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival (DMFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The DMFS is evaluated and calculated from the date of initiation treatment until the day of first distant metastases or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment related acute complications</measure>
    <time_frame>up to 3 months</time_frame>
    <description>treatment-related adverse events will be assessed by NCI-CTC5.0 criteria and RTOG/EORTC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment related late complications</measure>
    <time_frame>up to 5 years</time_frame>
    <description>treatment-related adverse events will be assessed by NCI-CTC5.0 criteria and RTOG/EORTC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>up to 5 years</time_frame>
    <description>efficacy will be measured by PERCIST1.0 and RECIST1.1 criteria.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The correlation between the radiotherapy dose with biomarkers such as peripheral blood lymphocyte and EBV-DNA.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Reduced dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients achieving CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Reduced dose</intervention_name>
    <description>The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.</description>
    <arm_group_label>Reduced dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional dose</intervention_name>
    <description>The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.</description>
    <arm_group_label>Conventional dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.</description>
    <arm_group_label>Conventional dose group</arm_group_label>
    <arm_group_label>Reduced dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathology confirmed nasopharyngeal squamous cell carcinoma.&#xD;
&#xD;
          2. Stage I-IVA（8thAJCC/UICC staging system).&#xD;
&#xD;
          3. Aged 18-80 years.&#xD;
&#xD;
          4. KPS≥70.&#xD;
&#xD;
          5. Have measurable lesions on 18F-FDG PET/CT before treatment.&#xD;
&#xD;
          6. HGB≥90 g/L，ANC≥1.5×109 /L，PLT≥80×109 /L.&#xD;
&#xD;
          7. ALT,AST&lt;2.5 fold of ULN；TBIL&lt;2.0×ULN.&#xD;
&#xD;
          8. CCR≥60ml/min or Cr&lt;1.5×ULN.&#xD;
&#xD;
          9. Signed informed consent.&#xD;
&#xD;
         10. Have follow up condition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past malignancies history (except for stage I non-melanoma skin cancer or cervical&#xD;
             carcinoma in situ).&#xD;
&#xD;
          2. Age &lt;18 or &gt;80years.&#xD;
&#xD;
          3. Pregnancy or lactation.&#xD;
&#xD;
          4. History of previous radiotherapy (except for non-melanomatous skin cancers outside&#xD;
             intended RT treatment volume).&#xD;
&#xD;
          5. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.&#xD;
&#xD;
          6. With sever infection and internal disease.&#xD;
&#xD;
          7. Major organ dysfunction, such as decompensated cardiopulmonary, kidney, liver failure,&#xD;
             cannot tolerate surgical treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haihua Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taizhou Enze Medical Center (Group) Enze Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haihua Yang, MD</last_name>
    <phone>13819639006</phone>
    <email>yhh93181@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taizhou Central Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>317000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shenpeng Ying</last_name>
      <phone>13957608158</phone>
    </contact>
    <investigator>
      <last_name>Shenpeng Ying</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bo Wu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>317000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haihua Yang, MD</last_name>
      <phone>+86 13819639006</phone>
      <email>yhh93181@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Weijun Ding</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian Zhu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Cancer Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>317500</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guangxian You, MD</last_name>
      <phone>13676668511</phone>
    </contact>
    <investigator>
      <last_name>Guangxian You</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linggang Zhu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Enze Medical Center(Group) Enze Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>318050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haihua Yang, MD</last_name>
      <phone>+86 13819639006</phone>
      <email>yhh93181@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Haihua Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiate Zhou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taizhou Hospital</investigator_affiliation>
    <investigator_full_name>Haihua Yang</investigator_full_name>
    <investigator_title>Head of Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

